A “first-of-its kind” quality of life study to be presented at ASCO this year is a year-long, randomized, three-arm trial of the value of “purposeful” physical exercise in the management of men on androgen deprivation therapy (ADT) for progressive prostate cancer. This study by Galvao et al. (see abstract no. 5037) is a multi-center, controlled […]![]()
